INmune Bio Inc. (INMB) announced that it received approval from the FDA to proceed on its clinical trial program for Alzheimer's disease, which was previously put on hold. The phase II trial is progressing according to plan, with the company intending to enroll its final patient by mid-2024. Preliminary results can be anticipated around six months after the final enrolment.
RJ Tesi, the CEO of INmune Bio, aims to complete the Phase II program in 2024 before engaging in an end-of-Phase II meeting with the FDA early the following year. This meeting is expected to solidify plans for a global Phase III trial, with sites projected in the U.S., Canada, U.K., E.U., and the Pacific Rim.
Stay updated with more health news at rttnews.com.
